A Phase 1 interventional study of ACHN-975 and placebo in Healthy Volunteer, sponsored by Achaogen, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-21.
Sponsored by Achaogen, Inc. · Phase 1, Interventional, and Treatment
This is a double-blind, randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability, and PK of ACHN-975 in normal healthy volunteers. This study will take place in the US at one clinical site.
Achaogen, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: ACHN-975
Drug: placebo
Intravenous single dose
Intravenous single dose
Frequency of AEs
Time frame: 7 days
Severity of AEs
Time frame: 7 days
Plasma concentrations of ACHN-975
Time frame: 2 days
Urine concentrations of ACHN-975
Time frame: 2 days
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Achaogen, Inc.